Purinergic signaling: a potential therapeutic target for ischemic stroke

Purinergic Signal. 2023 Mar;19(1):173-183. doi: 10.1007/s11302-022-09905-y. Epub 2022 Nov 12.


Pathogenesis of ischemic stroke is mainly characterized by thrombosis and neuroinflammation. Purinergic signaling pathway constitutes adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), and adenosine (ADO). ATP is hydrolyzed to ADP and then to AMP by extracellular nucleotidase CD39; AMP is subsequently converted to adenosine by CD73. All these nucleotides and nucleosides act on purinergic receptors protecting against thrombosis and inhibit inflammation. In addition, many physical methods have been found to play a neuroprotective role through purinergic signaling. This review mainly introduces the role and potential mechanism of purinergic signalings in the treatment of ischemic stroke, so as to provide reference for seeking new treatment methods for stroke.

Keywords: Adenosine; CD39; Ectonucleotidase; Ischemic stroke; Purinergic signaling.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 5'-Nucleotidase / metabolism
  • Adenosine / metabolism
  • Adenosine Diphosphate / metabolism
  • Adenosine Monophosphate / metabolism
  • Adenosine Triphosphate / metabolism
  • Antigens, CD / metabolism
  • Apyrase / metabolism
  • Humans
  • Ischemic Stroke*
  • Signal Transduction
  • Thrombosis*


  • Antigens, CD
  • Adenosine
  • Adenosine Triphosphate
  • Adenosine Diphosphate
  • Adenosine Monophosphate
  • 5'-Nucleotidase
  • Apyrase